FAAH
Signaling Pathway Map
Research Area
Inhibitory Selectivity
FAAH Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2631 |
URB597URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1. |
||
| S2666 |
PF-3845PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2. |
||
| S0497New |
JNJ-42165279JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively. |
||
| S5329 |
FAAH-IN-2FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH). |
||
| S6609 |
JZL195JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively. |
||
| S2421New |
PF-04457845PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily. |
||
| S2377 |
Biochanin ABiochanin A (4-Methylgenistein), an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. |
||
| S2828 |
JNJ-1661010JNJ-1661010 (Takeda-25) is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2. |
||
| S5932 |
BIA 10-2474BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor, with a potent inhibitory effect upon FAAH and prolonged action in vivo. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2631 |
URB597URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1. |
||
| S2666 |
PF-3845PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2. |
||
| S0497New |
JNJ-42165279JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively. |
||
| S5329 |
FAAH-IN-2FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH). |
||
| S6609 |
JZL195JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively. |
||
| S2421New |
PF-04457845PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily. |
||
| S2377 |
Biochanin ABiochanin A (4-Methylgenistein), an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. |
||
| S2828 |
JNJ-1661010JNJ-1661010 (Takeda-25) is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2. |
||
| S5932 |
BIA 10-2474BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor, with a potent inhibitory effect upon FAAH and prolonged action in vivo. |
